CD16+ neutrophils uniquely function as an inhibitor of antibody-dependent destruction of cancer cells, thereby identifying it as a potential target for enhancing the therapeutic efficacy of cancer therapeutic antibodies [48]. This evidence concerns the gene FCGR3A and cancer.